-

FDA Advisory Panel Backs Expanded Access to Certain Peptide Therapies
An FDA advisory panel has voiced support for broadening the availability of select peptide-based treatments, a signal that could pave the way for wider patient access. The recommendation reflects growing regulatory confidence in peptide therapeutics.
-

FDA Advisory Panel Signals Support for Compounded Peptide Access
An FDA advisory panel has reportedly recommended allowing continued compounding of certain unapproved peptides, a move that could preserve patient access to these therapies while formal approval pathways progress.
-

Retatrutide Shows Remarkable Weight-Loss Results, Rivaling Surgical Outcomes
Early clinical data on retatrutide, a new investigational peptide, show participants losing up to 30% of body weight—results comparable to bariatric surgery. Experts see this as a major step forward in non-surgical obesity treatment.
-

Understanding C-Peptide: A Key Biomarker Advancing Type 1 Diabetes Research
C-peptide, a byproduct of insulin production, is helping researchers better measure remaining beta-cell function in people with type 1 diabetes—supporting progress toward new therapies.
-

FDA Advisory Panel Recommends Easing Restrictions on Popular Peptides
An FDA advisory panel has voted to recommend loosening current restrictions on certain peptide compounds, a move that could expand access for patients and practitioners.
-
FDA Advisory Committee Backs Compounding for Six Popular Peptides
An FDA advisory panel has determined that six widely used peptides meet the criteria for pharmacy compounding, a step that could preserve patient access to these therapies through compounding pharmacies.
-
6 Popular Peptides May Soon Be Easier to Access, Report Suggests
A new report highlights that several popular peptides could soon become more accessible to consumers, reflecting growing mainstream interest in peptide therapies. Easier access could mean more people benefiting from these emerging treatments under proper guidance.
-
FDA Panel Vote Signals Potential for Easier Access to Popular Peptides
A recent FDA panel vote could pave the way for millions of Americans to gain easier access to popular peptide compounds, marking a potentially significant shift in regulatory approach.
-

GLP-1 Peptide Therapy Shows Promise in Reducing Heavy Drinking, Trial Finds
Altimmune’s GLP-1-based drug demonstrated a reduction in heavy drinking days among participants with alcohol use disorder in a recent clinical trial, opening a potential new avenue for treatment.
-
FDA Signals Broader Peptide Access—Minnesota Pharmacies Gear Up
Reports indicate the FDA may expand availability of certain peptides, prompting Minnesota compounding pharmacies to prepare for increased demand and patient access.